- Shanghai Nianxing Industrial Co., Ltd
- China
- Product Name: Fmoc-Hyp(Bom)-OH
- Price:
- Purity: 97.0%
- Stocking Period: 10 Day
- Contact: Yang
- Shanghai Jizhi Biochemical Technology Co., Ltd
- China
- Product Name: Fmoc-Hyp(Bom)-OH
- Price: ￥206.0/250mg ￥2736.0/10g ￥5576.0/25g ￥506.0/1g
- Purity: 97.0%
- Stocking Period: 2 Day
- Contact: Liu jia
- Chengdu Pukang Biotechnology Co., Ltd.
- China
- Product Name: FMOC-L-HYP(BOM)-OH
- Price: ￥Inquiry/10g
- Purity: 99.0%
- Stocking Period: 2 Day
- Contact: Lihua Yang
- DC Chemicals Limited
- China
- Product Name: Fmoc-Hyp(Bom)-OH
- Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/1g
- Purity: 98.0%
- Stocking Period: 3 Day
- Contact: Tony Cao
- Nanjing Peptide Biotech Ltd
- China
- Product Name: Fmoc-Hyp(Bom)-OH
- Price: ￥Inquiry/10g ￥Inquiry/100g ￥Inquiry/1kg ￥Inquiry/10kg
- Purity: 98.0%
- Stocking Period: 7 Day
- Contact: jom
187223-15-0
187223-15-0 structure
- Name: Fmoc-Hyp(Bom)-OH
- Chemical Name: fmoc-l-hyp(bom)-oh
- CAS Number: 187223-15-0
- Molecular Formula: C28H33N3O8
- Molecular Weight: 539.577
- Catalog: Signaling Pathways Antibody-drug Conjugate ADC Linker
- Create Date: 2016-11-18 09:55:42
- Modify Date: 2024-01-02 17:51:01
-
Fmoc-Hyp(Bom)-OH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Hyp(Bom)-OH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1]<
| Name | fmoc-l-hyp(bom)-oh |
|---|---|
| Synonyms |
1,2-Pyrrolidinedicarboxylic acid, 4-[[[[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]carbonyl]oxy]-, 1-(9H-fluoren-9-ylmethyl) ester, (2S,4R)-
1-[(9H-Fluoren-9-ylmethoxy)carbonyl]-4-({[2-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)ethyl]carbamoyl}oxy)proline Fmoc-(2S,4R)-Pro(4-OCO-NH-CH2-CH2-NH-Boc)-OH 1,2-Pyrrolidinedicarboxylic acid, 4-[[[[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]carbonyl]oxy]-, 1-(9H-fluoren-9-ylmethyl) ester (4R)-1-[(9H-Fluoren-9-ylmethoxy)carbonyl]-4-({[2-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)ethyl]carbamoyl}oxy)-L-proline Fmoc-Hyp(Bcc)-OH Fmoc-(2S,4R)-(4-OCO-NH-CH2-CH2-NH-Boc)-Pro-OH (2S,4R)-4-[[[[2-[[(1,1-Dimethylethoxy)carbonyl]amino]ethyl]amino]carbonyl]oxy]-1,2-pyrrolidinedicarboxylic acid 1-(9H-fluoren-9-ylmethyl) ester Fmoc-Hyp(Bom)-OH |
| Description | Fmoc-Hyp(Bom)-OH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Hyp(Bom)-OH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1]< |
|---|---|
| Related Catalog | |
| Target |
Cleavable |
| In Vitro | ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1]. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2]. |
| References |
| Density | 1.35±0.1 g/cm3 |
|---|---|
| Boiling Point | 749.0±60.0 °C at 760 mmHg |
| Molecular Formula | C28H33N3O8 |
| Molecular Weight | 539.577 |
| Flash Point | 406.8±32.9 °C |
| Exact Mass | 539.226746 |
| PSA | 143.50000 |
| LogP | 3.54 |
| Vapour Pressure | 0.0±2.6 mmHg at 25°C |
| Index of Refraction | 1.620 |
| Water Solubility | Insuluble (1.5E-3 g/L) (25 ºC) |
|
~%
187223-15-0 |
| Literature: NOVARTIS AG; NOVARTIS PHARMA GMBH Patent: WO2004/52817 A1, 2004 ; Location in patent: Page 19-20 ; |
|
~70%
187223-15-0 |
| Literature: Lewis, Ian; Bauer, Wilfried; Albert, Rainer; Chandramouli, Nagarajan; Pless, Janos; Weckbecker, Gisbert; Bruns, Christian Journal of Medicinal Chemistry, 2003 , vol. 46, # 12 p. 2334 - 2344 |
|
~%
187223-15-0 |
| Literature: Lewis, Ian; Bauer, Wilfried; Albert, Rainer; Chandramouli, Nagarajan; Pless, Janos; Weckbecker, Gisbert; Bruns, Christian Journal of Medicinal Chemistry, 2003 , vol. 46, # 12 p. 2334 - 2344 |
|
~%
187223-15-0 |
| Literature: Lewis, Ian; Bauer, Wilfried; Albert, Rainer; Chandramouli, Nagarajan; Pless, Janos; Weckbecker, Gisbert; Bruns, Christian Journal of Medicinal Chemistry, 2003 , vol. 46, # 12 p. 2334 - 2344 |
|
~%
187223-15-0 |
| Literature: Lewis, Ian; Bauer, Wilfried; Albert, Rainer; Chandramouli, Nagarajan; Pless, Janos; Weckbecker, Gisbert; Bruns, Christian Journal of Medicinal Chemistry, 2003 , vol. 46, # 12 p. 2334 - 2344 |
|
~%
187223-15-0 |
| Literature: Lewis, Ian; Bauer, Wilfried; Albert, Rainer; Chandramouli, Nagarajan; Pless, Janos; Weckbecker, Gisbert; Bruns, Christian Journal of Medicinal Chemistry, 2003 , vol. 46, # 12 p. 2334 - 2344 |
|
~%
187223-15-0 |
| Literature: Lewis, Ian; Bauer, Wilfried; Albert, Rainer; Chandramouli, Nagarajan; Pless, Janos; Weckbecker, Gisbert; Bruns, Christian Journal of Medicinal Chemistry, 2003 , vol. 46, # 12 p. 2334 - 2344 |
| Precursor 5 | |
|---|---|
| DownStream 0 | |